Published in Br Heart J on June 01, 1991
How good is your defibrillation technique? J R Soc Med (2005) 0.77
Analysis of transthoracic impedance during real cardiac arrest defibrillation attempts in older children and adolescents: are stacked-shocks appropriate? Resuscitation (2010) 0.75
The specific resistance of biological material--a compendium of data for the biomedical engineer and physiologist. Med Biol Eng (1967) 4.63
Termination of ventricular fibrillation in dogs by depolarizing a critical amount of myocardium. Am J Cardiol (1975) 1.93
Ventricular defibrillation -- a comparative trial using 175-J and 320-J shocks. N Engl J Med (1982) 1.38
Contractures and increase in internal longitudianl resistance of cow ventricular muscle induced by hypoxia. Circ Res (1979) 1.24
Amplitude of ventricular fibrillation waveform and outcome after cardiac arrest. Ann Intern Med (1985) 1.23
Influence of time and therapy on ventricular defibrillation in dogs. Crit Care Med (1980) 1.12
Transthoracic ventricular defibrillation in adults. Br Med J (1977) 1.09
Transthoracic resistance in human defibrillation. Influence of body weight, chest size, serial shocks, paddle size and paddle contact pressure. Circulation (1981) 1.04
Energy, current, and success in defibrillation and cardioversion: clinical studies using an automated impedance-based method of energy adjustment. Circulation (1988) 1.02
Defibrillator electrode-chest wall coupling agents: influence on transthoracic impedance and shock success. J Am Coll Cardiol (1985) 0.98
Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies. J Am Coll Cardiol (1986) 0.96
Time course of vulnerability to fibrillation after experimental coronary occlusion. Am J Cardiol (1971) 0.89
Chemical ventricular defibrillation of the human heart with bretylium tosylate. Am J Cardiol (1973) 0.89
Advance prediction of transthoracic impedance in human defibrillation and cardioversion: importance of impedance in determining the success of low-energy shocks. Circulation (1984) 0.89
Survival to leave hospital from ventricular fibrillation. Am Heart J (1986) 0.87
Transthoracic impedance to direct current discharge: effect of repeated countershocks. Med Instrum (1976) 0.86
Factors determining success and energy requirements for cardioversion of atrial fibrillation: revised version. Q J Med (1991) 0.84
The prediction of the impedance of the thorax to defibrillating current. Med Instrum (1976) 0.84
Determinants of defibrillation: prospective analysis of 183 patients. Am J Cardiol (1983) 0.83
Effect of ischemia, hypertrophy, hypoxia, acidosis, and alkalosis on canine defibrillation. Am J Physiol (1983) 0.83
Current-based versus energy-based ventricular defibrillation: a prospective study. J Am Coll Cardiol (1988) 0.81
Effects of electrophysiologic studies resulting in electrical countershock or burst pacing on left ventricular systolic and diastolic function. Am Heart J (1988) 0.80
The decrease in transthoracic impedance during successive ventricular defibrillation trials. Med Instrum (1975) 0.79
The interelectrode electrical resistance at defibrillation. Scand J Thorac Cardiovasc Surg (1972) 0.78
Antifibrillatory effects of lidocaine and bretylium immediately postcardiopulmonary resuscitation. Am Heart J (1985) 0.78
The effect of newer antiarrhythmic drugs on defibrillation threshold. Crit Care Med (1980) 0.77
Evaluation of transthoracic countershock with initial energy levels up to 200 J in a coronary care unit. J Electrocardiol (1985) 0.77
Increased ventricular fibrillation threshold with severe myocardial ischemia. Am Heart J (1982) 0.77
Initial experience with a microprocessor controlled current based defibrillator. Br Heart J (1989) 0.77
Ventricular fibrillation: the importance of being coarse? J Electrocardiol (1984) 0.77
Alteration of defibrillation threshold by antiarrhythmic drugs: a theoretical framework. Crit Care Med (1981) 0.77
Acute phase of myocardial infarction. Lancet (1971) 4.05
Management of ventricular fibrillation outside hospital. Lancet (1969) 3.07
Prognosis after recovery from ventricular fibrillation complicating ischaemic heart-disease. Lancet (1967) 2.97
The clinical pharmacology of mexiletine. Br J Clin Pharmacol (1978) 2.56
Autonomic disturbance at onset of acute myocardial infarction. Br Med J (1972) 2.50
Incidence, significance, and management of early bradyarrhythmia complicating acute myocardial infarction. Lancet (1968) 2.08
Chronic Q fever endocarditis. Br Heart J (1980) 2.03
Long-term prognosis following ventricular fibrillation in acute ischaemic heart disease. Br Med J (1970) 1.99
Optimizing the initial 12-lead electrocardiographic diagnosis of acute myocardial infarction. Eur Heart J (2000) 1.93
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83
ST depression only on the initial 12-lead ECG: early diagnosis of acute myocardial infarction. Eur Heart J (2001) 1.54
Electrical requirements for ventricular defibrillation. Br Med J (1975) 1.53
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation (1997) 1.47
Frequency analysis of ventricular fibrillation and resuscitation success. Q J Med (1992) 1.46
Management of complete heart block complicating acute myocardial infarction. Lancet (1967) 1.45
Pre-hospital coronary care. The mobile coronary care unit. Am J Cardiol (1969) 1.44
An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy. Am Heart J (1998) 1.41
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation (1999) 1.40
Suspected angina pectoris: a rapid-access chest pain clinic. QJM (2001) 1.28
Arrhythmias in the first hours of acute myocardial infarction. Prog Cardiovasc Dis (1981) 1.26
Anaphylactoid reaction after injection of alteplase. Lancet (1993) 1.25
Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet (1990) 1.20
Long-term oral antiarrhythmic therapy with mexiletine. Br Heart J (1978) 1.18
Deaths from ischaemic heart disease in Belfast. Br Heart J (1986) 1.18
Myocardial infarction in pregnancy. Int J Cardiol (1988) 1.14
Body-surface map models for early diagnosis of acute myocardial infarction. J Electrocardiol (1998) 1.14
The development of mexiletine in the management of ventricular dysrhythmias. Postgrad Med J (1977) 1.09
Transthoracic ventricular defibrillation in adults. Br Med J (1977) 1.09
Safe use of platelet GP IIb/IIIa inhibitors. Eur Heart J (1998) 1.07
Electrical energy requirements for ventricular defibrillation. Br Heart J (1978) 1.06
Symposium on arteriosclerotic heart disease. The prehospital phase of treatment for myocardial infarction. Geriatrics (1972) 1.05
Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J (1998) 1.04
Rounded biphasic waveform reduces energy requirements for transvenous catheter cardioversion of atrial fibrillation and flutter. Pacing Clin Electrophysiol (1997) 1.03
Transthoracic ventricular defibrillation in the adult. Med Instrum (1978) 1.03
Death and damage caused by multiple direct current shocks: studies in an animal model. Eur Heart J (1988) 1.02
A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction. Br Heart J (1989) 1.01
Circulatory effects of intravenous pentazocine in patients with acute myocardial infarction. Curr Ther Res Clin Exp (1971) 1.00
Mexiletine in the management of ventricular dysrhythmias. Eur J Cardiol (1977) 0.97
Mexiletine in normal volunteers. Br J Clin Pharmacol (1978) 0.97
Troponin T or troponin I as cardiac markers in ischaemic heart disease. Heart (2000) 0.97
Long-term survival after resuscitation from ventricular fibrillation occurring before hospital admission. Q J Med (1991) 0.96
Management of recurrent ventricular tachyarrhythmias associated with Q-T prolongation. Am J Cardiol (1981) 0.95
Age related outcome in acute myocardial infarction. Elderly people benefit from thrombolysis and should be included in trials. BMJ (1998) 0.92
A randomised dose ranging study of recombinant tissue plasminogen activator in acute myocardial infarction. Br Med J (Clin Res Ed) (1988) 0.91
Electrode pad size, transthoracic impedance and success of external ventricular defibrillation. Am J Cardiol (1989) 0.91
Initiation of ventricular fibrillation outside hospital in patients with acute ischaemic heart disease. Br Heart J (1982) 0.91
Prognosis after early discharge from hospital of patients with acute myocardial infarction. Br Heart J (1969) 0.91
Amiodarone-induced ventricular fibrillation. Eur J Cardiol (1980) 0.91
High dose nalbuphine in early acute myocardial infarction. Int J Cardiol (1989) 0.91
Survival of patients with late ventricular fibrillation after acute myocardial infarction. Lancet (1974) 0.90
Mortality within hospital after resuscitation from ventricular fibrillation outside hospital. Br Heart J (1992) 0.89
Cardiopulmonary resuscitation. European guidelines a retrograde step. BMJ (1993) 0.88
Ventricular defibrillation: appropriate energy levels. Circulation (1979) 0.88
Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era. J Am Coll Cardiol (1993) 0.87
Familial idiopathic congestive cardiomyopathy in three generations: a family study with eight affected members. Q J Med (1987) 0.87
Survival to leave hospital from ventricular fibrillation. Am Heart J (1986) 0.87
Diagnosis and risk stratification of patients with anginal pain and non-diagnostic electrocardiograms. QJM (1999) 0.87
Recurrence of ventricular fibrillation in acute ischemic heart disease. Circulation (1981) 0.87
High dose intravenous streptokinase in acute myocardial infarction--short and long term prognosis. Br Heart J (1986) 0.86
The treatment of ventricular arrhythmias in acute myocardial infarction. Br J Hosp Med (1979) 0.86
Fourier analysis of ventricular fibrillation of varied aetiology. Eur Heart J (1990) 0.85
Randomised comparison of electrode positions for cardioversion of atrial fibrillation. Heart (1999) 0.85
Early diagnosis of right ventricular or posterior infarction associated with inferior wall left ventricular acute myocardial infarction. Am J Cardiol (2000) 0.85
Factors determining success and energy requirements for cardioversion of atrial fibrillation. Q J Med (1990) 0.85
Factors determining success and energy requirements for cardioversion of atrial fibrillation: revised version. Q J Med (1991) 0.84
An external automatic device to detect ventricular fibrillation. Eur Heart J (1986) 0.84
Discrete subaortic stenosis. Br Heart J (1981) 0.84
Heart failure associated with infective endocarditis. A review of 40 cases. Br Heart J (1986) 0.84
Coronary patient--early treatment? Br Heart J (1980) 0.84
Nalbuphine versus diamorphine early in the course of suspected myocardial infarction. Eur Heart J (1987) 0.84
Observations on haemodynamic effects of mexiletine. Br Heart J (1979) 0.83
Myoglobin and creatine kinase in acute myocardial infarction. Br Heart J (1984) 0.83
Ventricular defibrillation: the Belfast experience. Br Heart J (1987) 0.83
Clinical Q fever in Northern Ireland 1962-1989. Ulster Med J (1990) 0.83
Hospital or home for acute myocardial infarction: another look at whether or not we should bother to care. Am Heart J (1981) 0.83
Changes in circulating immune complex concentrations and antibody titres during treatment of Q fever endocarditis. J Clin Pathol (1985) 0.82
Metabolic changes and mitochondrial dysfunction early following transthoracic countershock in dogs. Pacing Clin Electrophysiol (1989) 0.82
Ventricular fibrillation and its recurrence in early acute myocardial infarction. Lancet (1981) 0.82
Successful treatment by doxycycline of endocarditis caused by ornithosis. Br Heart J (1987) 0.81
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators. Am J Cardiol (1999) 0.81
Effect of nifedipine on enzymatically estimated infarct size in the early phase of acute myocardial infarction. Br Heart J (1988) 0.81
Warning arrhythmias in ischemic heart disease. Int J Cardiol (1983) 0.81
Primary angiosarcoma of the heart. Ir J Med Sci (1977) 0.81
Letter: Effect of lidocaine on "gating" mechanism. Am Heart J (1974) 0.80
Lipid peroxidation and antioxidant status following thrombolytic therapy for acute myocardial infarction. Eur Heart J (1993) 0.80
Transesophageal cardioversion. Am Heart J (1993) 0.80
Recurrent ventricular arrhythmias complicating myocardial infarction in the presence of phaeochromocytoma. Br Heart J (1992) 0.80
Clinical, echocardiographic, and operative findings in active infective endocarditis. Br Heart J (1982) 0.80
Q fever endocarditis in Northern Ireland. Lancet (1983) 0.80
Fourier analysis of ventricular fibrillation and synchronization of DC countershocks in defibrillation. J Electrocardiol (1988) 0.80
A cellular transtelephonic defibrillator for management of cardiac arrest outside the hospital. Am J Cardiol (1991) 0.79
A gastroesophageal electrode for atrial and ventricular pacing. Pacing Clin Electrophysiol (1997) 0.79
Long term oral antiarrhythmic therapy with mexiletine. Postgrad Med J (1977) 0.79
Time delays to lytic therapy and outcome in 100 consecutive patients with a history suggestive of acute myocardial infarction in an area with access to a mobile coronary care unit. Eur Heart J (1994) 0.79
Angiographic frame counts 90 minutes after streptokinase predict left ventricular function at 48 hours following myocardial infarction. Heart (1999) 0.79
Improving the ECG classification of inferior and lateral myocardial infarction by inversion of lead aVR. Heart (2000) 0.79
The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Expert Opin Investig Drugs (1999) 0.79
Intact removal of phytobezoar using fibreoptic endoscope in patient with gastric atony. Br Med J (1979) 0.78